Tandem Diabetes Care/$TNDM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Tandem Diabetes Care
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Ticker
$TNDM
Sector
Primary listing
Employees
2,650
Headquarters
Website
TNDM Metrics
BasicAdvanced
$1.1B
-
-$3.05
1.74
-
Price and volume
Market cap
$1.1B
Beta
1.74
52-week high
$38.28
52-week low
$9.98
Average daily volume
2M
Financial strength
Current ratio
2.443
Quick ratio
1.762
Long term debt to equity
325.532
Total debt to equity
341.582
Interest coverage (TTM)
-11.31%
Profitability
EBITDA (TTM)
-69.582
Gross margin (TTM)
53.23%
Net profit margin (TTM)
-20.20%
Operating margin (TTM)
-8.64%
Effective tax rate (TTM)
0.77%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-5.93%
Return on equity (TTM)
-109.73%
Valuation
Price to revenue (TTM)
1.078
Price to book
8.29
Price to tangible book (TTM)
8.29
Price to free cash flow (TTM)
-15.828
Free cash flow yield (TTM)
-6.32%
Free cash flow per share (TTM)
-1.027
Growth
Revenue change (TTM)
17.87%
Earnings per share change (TTM)
56.91%
3-year revenue growth (CAGR)
8.39%
10-year revenue growth (CAGR)
32.23%
3-year earnings per share growth (CAGR)
42.08%
10-year earnings per share growth (CAGR)
-20.15%
What the Analysts think about TNDM
Analyst ratings (Buy, Hold, Sell) for Tandem Diabetes Care stock.
TNDM Financial Performance
Revenues and expenses
TNDM Earnings Performance
Company profitability
TNDM News
AllArticlesVideos
ROSEN, A LEADING LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Newsfile Corp2 hours ago
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Newsfile Corp1 day ago
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Newsfile Corp3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tandem Diabetes Care stock?
Tandem Diabetes Care (TNDM) has a market cap of $1.1B as of November 10, 2025.
What is the P/E ratio for Tandem Diabetes Care stock?
The price to earnings (P/E) ratio for Tandem Diabetes Care (TNDM) stock is 0 as of November 10, 2025.
Does Tandem Diabetes Care stock pay dividends?
No, Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next Tandem Diabetes Care dividend payment date?
Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders.
What is the beta indicator for Tandem Diabetes Care?
Tandem Diabetes Care (TNDM) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.